Patent classifications
A61K47/6949
DISPERSIONS FOR ADDITIVE MANUFACTURING COMPRISING DISCRETE CARBON NANOTUBES
The present invention is directed to additive manufacturing compositions and methods for producing additive manufacturing composite blends with oxidized discrete carbon nanotubes with dispersion agents bonded to at least one sidewall of the oxidized discrete carbon nanotubes. Such compositions are especially useful when radiation cured, sintered or melt fused.
STING AGONIST-CONTAINING UREASE-POWERED NANOMOTOR-BASED BLADDER CANCER IMMUNOTHERAPY AGENT
A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.
Nanomaterial and Methods of Use Thereof
A self-assembled nanomaterial includes a Janus base nanotube and a biologically active molecule covalently or non-covalently adhered thereto, wherein the Janus base nanotube includes at least one compound represented by disclosed Formulas I, II, III, IV. V. VI, VII, VIII, or IX, or a pharmaceutically acceptable salt thereof.
METAL-ORGANIC FRAMEWORK MATERIALS AND USES OF THE METAL-ORGANIC FRAMEWORK MATERIALS
Embodiments of the invention provide modified metal-organic frameworks (MOF), materials and compositions comprising the modified metal-organic frameworks (MOF) and uses of the materials and compositions comprising modified MOFs. The modified MOFs may include a functionalizing constituent that provides enhanced functionality, such as transporting molecules across biological membranes. Embodiments of the modified MOF may comprise a magnesium-gallate (Mg-GA) network structure. The Mg-GA MOF may also comprise phosphate-functionalized polyethylene glycol, which comprises PEGylates (polyethylene glycol) with phosphate groups.
MICROSTRUCTURE FOR PREVENTION AND TREATMENT OF OBESITY AND OBESITY-DERIVED TYPE 2 DIABETES, COMPRISING COMPLEX OF GENE AND ADIPOCYTE-TARGETING GENE CARRIER
The present invention relates to a microstructure for the prevention and treatment of obesity and obesity-derived type 2 diabetes, comprising a complex of a gene and an adipocyte-targeting gene carrier. Being capable of suppressing the expression of FABP4 and FABP5 with the gene and the adipocyte-targeting gene carrier, the present invention can exhibit excellent prophylactic and therapeutic effects on obesity and obesity-derived type 2 diabetes.
Self-assembled complex containing copper ions
Disclosed is a self-assembled complex containing copper ions, including: copper ions; and one or more ligands, in which the ligands and the copper ions are reversibly self-assembled or self-degraded, and when there are a plurality of types of ligands or a plurality of ligands, the shape of the self-assembled complex is formed differently depending on the blending ratio of the ligands.